Glucagon-like peptide 1 (GLP-1) analogs have recently received much attention as a potential treatment for obese patients with type 2 diabetes (T2DM), and the early success of GLP-1 analogs suggests that the role of this gut peptide in the treatment of diabetes and obesity is set to expand. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.